MAIA Biotechnology Announces Efficacy Updates for THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
MAIA Biotechnology Amends Employment Agreements with Executive Officers
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) recently disclosed updates to the employment agreements of key executive officers in a Form 8-K filing dated February 1, 2025. The company entered into ...
MAIA Biotech executives receive salary hikes and new terms
In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has ...
CoreLogic: Home Price Growth Ticks up Slightly in December
CoreLogic®, a leading global property information, analytics and data-enabled solutions provider, today released the ...
Jim Cramer: Buy American Express (AXP) on Travel Strength
We recently published a list of Jim Cramer Discusses These 10 Stocks & President Trump’s Tariffs. In this article, we are ...